Clinical Trial Update: SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

View source ↗

Summary

This entry notes a recruiting clinical trial evaluating SPECT/CT imaging-based dosimetry to optimize Lutetium-177 PSMA-617 therapy for metastatic castration-res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Pluvicto (Lutetium-177-PSMA-617) (Lutetium-177-PSMA-617)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Metastatic Castration-Resistant Prostate Carcinoma | Status: RECRUITING